Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21198979 | 0.86 | CYP17A1 (0.43) | SOS1ALDH1A1PKMPDE2AKDM5A | |
| SCHEMBL2976327 | 0.77 | PDE2A (0.54) | ALDH1A1PDE2AKDM5B | |
| SCHEMBL574245 | 0.76 | ALDH1A1 (0.40) | ALDH1A1PKML3MBTL1HTR2AHTR2C | |
| SCHEMBL28407960 | 0.76 | ALDH1A1 (0.40) | ALDH1A1PKML3MBTL1HTR2AHTR2C | |
| SCHEMBL31478569 | 0.74 | KDM5A (0.33) | PDE2AKDM5AKDM5BSIGMAR1 | |
| SCHEMBL25202981 | 0.71 | HTR2A (0.48) | SOS1ALDH1A1PKML3MBTL1HTR2A | |
| SCHEMBL28290766 | 0.70 | ALDH1A1 (0.41) | ALDH1A1PKML3MBTL1HTR2AHTR2C | |
| SCHEMBL27453998 | 0.70 | HTR2A (0.35) | ALDH1A1PKML3MBTL1HTR2AHTR2C | |
| SCHEMBL28567016 | 0.69 | ALDH1A1 (0.32) | ALDH1A1PKMHTR2AHTR2CHTR2B | |
| SCHEMBL21199105 | 0.69 | SOS1 (0.39) | SOS1ALDH1A1PKML3MBTL1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | SOS1 4397/4885ALDH1A1 2569/4885PKM 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.